The world is in a hurry to produce a vaccine against Coronavirus
The two pharmaceutical companies will receive $2.1 billion to develop and deliver 100 million of the potential COVID-19 vaccine. The deal gives the US government the possibility to buy another 500 million doses at an undisclosed price. The current cost per patient is $42, and by the deal, each patient will receive two doses.
According to a joint statement released by the companies, more than half of the funding will be used to develop the vaccine and further the necessary processes, including the delivery of doses.
For the American government, this is the most significant payment made under "Operation Warp Speed," designed to accelerate access to treatments and vaccines against Coronavirus.
However, the Franco-British pair is at its second contract of this sort, after it made a deal with the British government to deliver 60 million vaccine doses.
Currently, there are more than 150 vaccines under development, out of which 25 are in clinical trials, according to WHO (World Health Organization). The magnitude of this virus made the pharmaceutical companies do the impossible, time-wise speaking, as the development of a vaccine usually takes about a decade. The record for the fastest vaccine development has been set at around four years. The immunization against mumps received the green light in 1967.
At the moment of writing, Sanofi stock price is trading lower by 0.04%, while GSK gained more than 1%.
Read all about the pharmaceutical companies on CAPEX.com, and don’t forget to check-out our Corona Blend!
Sources: cnbc.com, reuters.com
Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.
Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. El rendimiento pasado no es un indicador confiable de resultados futuros.